nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.12.2008

Diagnosis of Cystic Fibrosis

verfasst von: Karen Z. Voter, Clement L. Ren

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that results in abnormal viscous mucoid secretions in multiple organs and whose main clinical features are pancreatic insufficiency and chronic endobronchial infection. Although it was initially defined and diagnosed based on clinical features and sweat chloride measurement, an in vivo method of assessing CFTR function, the discovery of the CFTR gene in 1989 revealed a broad spectrum of CF phenotypes associated with specific CFTR gene mutations. In this article, we will review the indications for sweat testing, alternative techniques to diagnose CF, and the approach to patients with an ambiguous or indeterminate diagnosis of CF.

Davis PB, Drumm M, Konstan MW (1996) Cystic fibrosis. Am J Respir Crit Care Med 154:1229–1256PubMed

National Newborn Screening and Genetics Resource Center (2003) National newborn screening report 2000. National Newborn Screening and Genetics Resource Center, San Antonio, TX

Andersen D (1938) Cystic fibrosis of the pandrease and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56:344–399

Di Sant'Agnese P (2001) Experiences of a pioneer researcher: discovery of the sweat electrolyte defect and the early medical history of cystic fibrosis. In: Doershuk C (ed) Cystic fibrosis in the 20th century. People, events, and progress. AM, Cleveland, OH

Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23:545–549PubMed

Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132:589–595PubMedCrossRef

Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073PubMedCrossRef

Rowntree RK, Harris A (2003) The phenotypic consequences of CFTR mutations. Ann Hum Genet 67:471–485PubMedCrossRef

Davis PB (2001) Cystic fibrosis. Pediatr Rev 22:257–264PubMedCrossRef

10.

Cystic Fibrosis Foundation (2006) Cystic fibrosis foundation patient registry. Cystic Fibrosis Foundation, Bethesda, MD

11.

Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW et al (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005–1015PubMedCrossRef

12.

Wine JJ (1999) The genesis of cystic fibrosis lung disease. J Clin Invest 103:309–312PubMedCrossRef

13.

Ratjen F (2006) Restoring airway surface liquid in cystic fibrosis. N Engl J Med 354:291–293PubMedCrossRef

14.

LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr (2007) Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151:85–89PubMedCrossRef

15.

NCCLS (2000) Sweat testing: sample collection and quantitative analysis: approved guideline. National Committee for Clinical Laboratory Standards, Wayne, PA Document C34-A2. Clinical Laboratory Standards Institute formerly National Committee for Clinical Laboratory Standards

16.

Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M et al (2004) Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53:1–36

17.

Knowles MR, Durie PR (2002) What is cystic fibrosis? N Engl J Med 347:439–442PubMedCrossRef

18.

De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J et al (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635PubMedCrossRef

19.

Zeitlin PL (1999) Novel pharmacologic therapies for cystic fibrosis. J Clin Invest 103:447–452PubMedCrossRef

20.

Donaldson SH, Boucher RC (2007) Sodium channels and cystic fibrosis. Chest 132:1631–1636PubMedCrossRef

21.

Hamosh A, FitzSimmons SC, Macek M Jr., Knowles MR, Rosenstein BJ, Cutting GR (1998) Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 132:255–259PubMedCrossRef

22.

Wine JJ, Kuo E, Hurlock G, Moss RB (2001) Comprehensive mutation screening in a cystic fibrosis center. Pediatrics 107:280–286PubMedCrossRef

23.

Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A et al (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487–496PubMedCrossRef

24.

Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ (1993) Mutations in CFTR associated with mild-disease-form Cl− channels with altered pore properties. Nature 362:160–164PubMedCrossRef

25.

O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R (2006) Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics 118:1260–1265PubMedCrossRef

26.

Ren CL (2007) Pulmonary manifestations in deltaF508/R117H. Pediatrics 119:647–648PubMedCrossRef

27.

Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A et al (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331:974–980PubMedCrossRef

28.

Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM (1990) Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 3:922–926PubMed

29.

Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6:445–455PubMedCrossRef

30.

Sauder RA, Chesrown SE, Loughlin GM (1987) Clinical application of transepithelial potential difference measurements in cystic fibrosis. J Pediatr 111:353–358PubMedCrossRef

31.

Wagener JS, Sontag MK, Accurso FJ (2003) Newborn screening for cystic fibrosis. Curr Opin Pediatr 15:309–315PubMedCrossRef

Titel: Diagnosis of Cystic Fibrosis
verfasst von: Karen Z. Voter
Clement L. Ren
Publikationsdatum: 01.12.2008
Verlag: Humana Press Inc
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 3/2008
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-008-8078-x

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Diagnosis of Cystic Fibrosis

Abstract

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Atypical Cystic Fibrosis and CFTR-Related Diseases

Newborn Screening for Cystic Fibrosis

Gene Therapy for Cystic Fibrosis

Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease

Cystic Fibrosis: Evolution from a Fatal Disease of Infancy with a Clear Phenotype to a Chronic Disease of Adulthood with Diverse Manifestations

Overview of Lung Transplantation

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO